Elevated expression levels of RCC2, SERBP1, and MAD2L1 were positively correlated with poor prognosis and shorter survival times in breast cancer patients (Figure7A), suggesting that they may serve as biomarkers for clinical prognosis assessment. This evidence concerns the gene RCC2 and breast carcinoma.